Emerging Therapies eBook
Read the article: Navigating the Intricacies of Lentiviral CGTs
Read the eBook: BioPharm International’s September 2023 Emerging Therapies eBook
Navigating the Intricacies of Lentiviral CGTs
Publication
Article
BioPharm InternationalEmerging Therapies, September 2023 eBook
Volume 2023 eBook
Issue 3
Pages: 14–17
Scientists are leveraging ddPCR technology to get an accurate read on viral titer and vector copy number.
bluebay2014 - stock.adobe.com
Cell and gene therapies (CGTs) can potentially treat, and sometimes even cure, a wide range of genetic and acquired diseases ranging from immunodeficiencies to cancer. For this reason, the field has been growing at an astronomical rate. Having impeccable data about the makeup of a new therapeutic is vital to successful clinical trials that take a new drug candidate one step closer to FDA approval. But the myriad designs of CGTs in development today make that uniquely challenging. In this article, the author will explore some of the specific hurdles associated with lentiviral CGTs.
Read this article in BioPharm International®’s September 2023 Emerging Therapies eBook.
About the author
Marwan Alsarraj is biopharma segment manager, Digital Biology Group, Bio-Rad.
Article details
BioPharm International
eBook: Emerging Therapies
September 2023
Pages: 14–17
Citation
When referring to this article, please cite it as Alsarraj, M. Navigating the Intricacies of Lentiviral CGTs. BioPharm International’s Emerging Therapies eBook. September 2023.
Recent Videos
Related Content
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025Article
The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
